Live from the NIH registry
Studies recruiting near Flint right now
Top 25 of 181 recruiting studies, sorted by proximity — each links to its official registry page
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Systemic Lupus Erythematosus
Phase 3
Interventional 550 participants sought
Ahmed Arif Medical Research Center — Grand Blanc, Michigan (7.3 mi)
· Sponsor: Novartis Pharmaceuticals
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Geographic Atrophy, Macular Degeneration
N/A
Observational 500 participants sought
Retina Associates of Michigan — Grand Blanc, Michigan (7.3 mi)
· Sponsor: Astellas Pharma Global Development, Inc.
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Phase 3
Interventional 340 participants sought
Aa Mrc Llc — Flint, Michigan (0.8 mi)
· Sponsor: Novartis Pharmaceuticals
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Multiple conditions
Phase 2
Interventional 150 participants sought
Cancer Hematology Centers - Flint — Flint, Michigan (0.8 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NonSegmental Vitiligo
Phase 3
Interventional 180 participants sought
Dermatology and Cosmetic Center — Flint, Michigan (0.8 mi)
· Sponsor: Incyte Corporation
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
Phase 2
Interventional 93 participants sought
Cancer Hematology Centers - Flint — Flint, Michigan (0.8 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Phase 3
Interventional 1,450 participants sought
Cancer Hematology Centers - Flint — Flint, Michigan (0.8 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Type 1 Diabetes Mellitus With Hypoglycemia
Phase 2
Interventional 186 participants sought
Elite Research Center — Flint, Michigan (0.8 mi)
· Sponsor: Zucara Therapeutics Inc.
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Phase 3
Interventional 600 participants sought
Cancer Hematology Centers - Flint — Flint, Michigan (0.8 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Phase 3
Interventional 255 participants sought
Genesys Hurley Cancer Institute — Flint, Michigan (0.8 mi)
· Sponsor: National Cancer Institute (NCI)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2
Interventional 2,000 participants sought
Cancer Hematology Centers - Flint — Flint, Michigan (0.8 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Phase 2
Interventional 405 participants sought
AA MRC LLC - Grand Blanc — Grand Blanc, Michigan (7.3 mi)
· Sponsor: Boehringer Ingelheim
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
N/A
Interventional 1,956 participants sought
McLaren Cancer Institute-Flint — Flint, Michigan (0.8 mi)
· Sponsor: NRG Oncology
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
N/A
Observational 2,000 participants sought
Cancer Hematology Centers - Flint — Flint, Michigan (0.8 mi)
· Sponsor: Wake Forest University Health Sciences
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Pancreatic Cancer
Phase 2
Interventional 60 participants sought
McLaren Proton Therapy Center — Flint, Michigan (0.8 mi)
· Sponsor: Proton Collaborative Group
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Prostate Cancer (Adenocarcinoma)
Phase 3
Interventional 830 participants sought
McLaren Cancer Institute-Flint — Flint, Michigan (0.8 mi)
· Sponsor: Canadian Cancer Trials Group
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Stage I Breast Cancer
Phase 3
Interventional 1,670 participants sought
Genesys Hurley Cancer Institute — Flint, Michigan (0.8 mi)
· Sponsor: NRG Oncology
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Breast Cancer, Cognitive Impairments
N/A
Interventional 386 participants sought
Cancer Hematology Centers - Flint — Flint, Michigan (0.8 mi)
· Sponsor: NRG Oncology
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial Meningioma, Recurrent Meningioma
Phase 2
Interventional 124 participants sought
Cancer Hematology Centers - Flint — Flint, Michigan (0.8 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Secukinumab Open Label Roll-over Extension Protocol
Autoimmunity, Inflammation
Phase 4
Interventional 1,000 participants sought
Ahmed Arif Medical Research Center — Grand Blanc, Michigan (7.3 mi)
· Sponsor: Novartis Pharmaceuticals
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Extensive Stage Lung Small Cell Carcinoma
Phase 2, Phase 3
Interventional 138 participants sought
Genesys Hurley Cancer Institute — Flint, Michigan (0.8 mi)
· Sponsor: National Cancer Institute (NCI)
Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM
Epiretinal Membrane
N/A
Interventional 400 participants sought
Retina Associates of Michigan — Grand Blanc, Michigan (7.3 mi)
· Sponsor: Jaeb Center for Health Research
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
Phase 3
Interventional 200 participants sought
McLaren Cancer Institute-Flint — Flint, Michigan (0.8 mi)
· Sponsor: NRG Oncology
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Atopic Dermatitis
Phase 3
Interventional 195 participants sought
Leo Pharma Investigational site — Waterford, Michigan (26.9 mi)
· Sponsor: LEO Pharma
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
Cancer Hematology Centers - Flint — Flint, Michigan (0.8 mi)
· Sponsor: National Cancer Institute (NCI)